{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:27:52Z","timestamp":1771954072840,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ebiomedicine.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ebiom.2017.05.024","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T07:01:53Z","timestamp":1495522913000},"page":"206-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity"],"prefix":"10.1016","volume":"21","author":[{"given":"Carol","family":"Chen-Scarabelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Corsetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evasio","family":"Pasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco S.","family":"Dioguardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gagan","family":"Sahni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagat","family":"Narula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Gavazzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemang","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Saravolatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Raddino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziano M.","family":"Scarabelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ebiom.2017.05.024_bb0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","article-title":"Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study","volume":"124","author":"Bringhen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2017.05.024_bb0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0160-5402(79)90038-X","article-title":"The Langendorff heart preparation: reappraisal of its role as a research and teaching model for coronary vasoactive drugs","volume":"2","author":"Broadley","year":"1979","journal-title":"J. Pharmacol. Methods"},{"key":"10.1016\/j.ebiom.2017.05.024_bb0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.abb.2015.12.012","article-title":"Mammalian proteasome subtypes: their diversity in structure and function","volume":"591","author":"Dahlmann","year":"2016","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ebiom.2017.05.024_bb0020","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res."},{"issue":"Suppl","key":"10.1016\/j.ebiom.2017.05.024_bb0025","article-title":"Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): results from the phase III study ENDEAVOR","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ebiom.2017.05.024_bb0030","article-title":"Carfilzomib and dexamethasone improves progression-free survival and response rates vs bortezomib and dexamethasone in patients (PTS) with relapsed multiple myeloma (RMM): The phase 3 study ENDEAVOR","volume":"100","author":"Dimopoulos","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.ebiom.2017.05.024_bb0035","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1161\/01.CIR.94.10.2587","article-title":"Metabolic adaptation during a sequence of no-flow and low-flow ischemia. A possible trigger for hibernation","volume":"94","author":"Ferrari","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ebiom.2017.05.024_bb0040","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/288373a0","article-title":"The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine","volume":"288","author":"Furchgott","year":"1980","journal-title":"Nature"},{"issue":"28","key":"10.1016\/j.ebiom.2017.05.024_bb0045","doi-asserted-by":"crossref","first-page":"24733","DOI":"10.18632\/oncotarget.4619","article-title":"The 26S proteasome is a multifaceted target for anti-cancer therapies","volume":"6","author":"Grigoreva","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.ebiom.2017.05.024_bb0050","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/CIRCRESAHA.107.152959","article-title":"Chronic proteasome inhibition contributes to coronary atherosclerosis","volume":"101","author":"Herrmann","year":"2007","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.ebiom.2017.05.024_bb0055","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/eurjhf\/hft034","article-title":"Primary proteasome inhibition results in cardiac dysfunction","volume":"15","author":"Herrmann","year":"2013","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.ebiom.2017.05.024_bb0060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2017.05.024_bb0065","series-title":"KYPROLIS (Carfilzomib) [Prescribing Information]","year":"2015"},{"key":"10.1016\/j.ebiom.2017.05.024_bb0070","series-title":"KYPROLIS [Prescribing Information]","year":"2016"},{"issue":"2","key":"10.1016\/j.ebiom.2017.05.024_bb0075","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/gerona\/63.2.200","article-title":"Effects of ubiquitin-proteasome system deregulation on the vascular senescence and atherosclerosis process in elderly patients","volume":"63","author":"Marfella","year":"2008","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"18","key":"10.1016\/j.ebiom.2017.05.024_bb0080","doi-asserted-by":"crossref","first-page":"10403","DOI":"10.1073\/pnas.96.18.10403","article-title":"Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity","volume":"96","author":"Meng","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.ebiom.2017.05.024_bb0085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjh.13296","article-title":"Phase Ib\/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma","volume":"169","author":"Mikhael","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ebiom.2017.05.024_bb0090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-319-40320-5_10","article-title":"Treatment of relapsed\/refractory multiple myeloma","volume":"169","author":"Neri","year":"2016","journal-title":"Cancer Treat. Res."},{"issue":"4","key":"10.1016\/j.ebiom.2017.05.024_bb0095","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00005344-199704000-00006","article-title":"Mechanism of action of human calcitonin gene-related peptide in rabbit heart and in human mammary arteries","volume":"29","author":"Raddino","year":"1997","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"11","key":"10.1016\/j.ebiom.2017.05.024_bb0100","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ebiom.2017.05.024_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ebiom.2017.05.024_bb0110","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ebiom.2017.05.024_bb0115","doi-asserted-by":"crossref","first-page":"403407","DOI":"10.1038\/nature01071","article-title":"A cryptic protease couples deubiquitination and degradation by the proteasome","volume":"419","author":"Yao","year":"2002","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ebiom.2017.05.024_bb0120","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1158\/1535-7163.MCT-13-0156","article-title":"In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome","volume":"12","author":"Zhang","year":"2013","journal-title":"Mol. Cancer Ther."}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396417302220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396417302220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T14:55:27Z","timestamp":1535813727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396417302220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":24,"alternative-id":["S2352396417302220"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2017.05.024","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2017.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}